Postpartum atypical hemolytic uremic syndrome with complement factor H mutation complicated by reversible cerebrovascular constriction syndrome successfully treated with eculizumab

Thromb Res. 2017 Mar:151:79-81. doi: 10.1016/j.thromres.2017.01.013. Epub 2017 Feb 2.

Authors

Makoto Yamaguchi¹, Mayuko Hori¹, Nagaya Hiroshi¹, Shoichi Maruyama²

Affiliations

¹ Municipal Yokkaichi Hospital, Yokkaichi, Japan.
² Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: [email protected].

PMID: 28167400
DOI: 10.1016/j.thromres.2017.01.013

No abstract available

Keywords: Atypical hemolytic uremic syndrome; Complement factor H; Eculizumab; Pregnancy.

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Atypical Hemolytic Uremic Syndrome / drug therapy*
Atypical Hemolytic Uremic Syndrome / genetics
Atypical Hemolytic Uremic Syndrome / pathology
Complement Factor H / genetics
Complement Factor H / metabolism
Female
Humans
Mutation
Postpartum Period

Substances

Antibodies, Monoclonal, Humanized
CFH protein, human
Complement Factor H
eculizumab